Article
The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
British journal of haematology - 1 Jun 2017
Kayastha Gyan K, Ranjitkar Nora, Gurung Radha, Kc Raj Kumar, Karki Sanjit, Shrestha Roshan, Rajbhandari Piyush, Thapa Raj K, Poudyal Buddhi, Acharya Paras, Roberts David J, Hayes Bruce, Zimmerman Mark, Basnyat Buddha
Abstract excerpt
Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia (CML) can be successfully treated with Glivec (Imatinib), which is available free of cost through the Glivec International Patient Assistance programme (GIPAP) to patients with proven CML without means to pay for the drug. We review the acquired mutations in the tyrosine kinase encoded by the BCR-ABL1 gene underlying Glivec failure or resistance...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.